Bristol-Myers Squibb Company

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products globally. The company focuses on therapeutic areas such as oncology, hematology, immunology, cardiovascular, and neuroscience. Its key products include Opdivo for anti-cancer indications, Orencia for rheumatoid arthritis, Yervoy for melanoma, Eliquis for stroke prevention, and Revlimid for multiple myeloma. The portfolio also features newer treatments like Camzyos for obstructive hypertrophic cardiomyopathy, Zeposia for multiple sclerosis, and Cobenfy for schizophrenia. Bristol-Myers Squibb serves patients worldwide through a broad range of innovative medicines.

Bristol-Myers Squibb Company is listed on the New York Stock Exchange (NYSE) under the ticker symbol BMY. The company is based in the United States and its stock is traded in US Dollars (USD). As a US-based company, BMY is part of the US region and its financial reporting is conducted in USD, making it accessible to investors through major US brokerage platforms.

Bristol-Myers Squibb operates in the Healthcare sector, specifically within the Drug Manufacturers - General industry. This classification means the company is primarily engaged in the research, development, production, and sale of pharmaceutical drugs. As a general drug manufacturer, BMY covers a wide range of therapeutic areas, including oncology, immunology, cardiovascular, and neuroscience, distinguishing it from companies that focus on a single disease area.

Bristol-Myers Squibb is headquartered in the United States and operates globally. The company's description indicates it discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. While specific country-level details are not provided, its global presence is evident from its broad product portfolio that addresses diseases prevalent across multiple regions, including oncology, cardiovascular, and autoimmune conditions.

Bristol-Myers Squibb's portfolio includes a wide array of biopharmaceutical products across several therapeutic areas. Key products include Opdivo (anti-cancer), Orencia (rheumatoid arthritis), Yervoy (melanoma), Eliquis (stroke prevention), Revlimid (multiple myeloma), and Pomalyst/Imnovid (multiple myeloma). The company also offers newer treatments such as Camzyos (obstructive hypertrophic cardiomyopathy), Zeposia (multiple sclerosis), Sotyktu (plaque psoriasis), Krazati (non-small cell lung cancer), Cobenfy (schizophrenia), Breyanzi (large B-cell lymphoma), Abecma (multiple myeloma), and Augtyro (ROS1-positive NSCLC). These products address serious diseases in oncology, immunology, cardiovascular, and neuroscience.